Understanding the Neurocomputational Mechanisms of Antidepressant Placebo Effects
- PMID: 33732892
- PMCID: PMC7963355
- DOI: 10.20900/jpbs.20210001
Understanding the Neurocomputational Mechanisms of Antidepressant Placebo Effects
Abstract
Over the last two decades, neuroscientists have used antidepressant placebo probes to examine the biological mechanisms implicated in antidepressant placebo effects. However, findings from these studies have not yet elucidated a model-based theory that would explain the mechanism through which antidepressant expectancies evolve to induce persistent mood changes. Emerging evidence suggests that antidepressant placebo effects may be informed by models of reinforcement learning (RL). Such that an individual's expectation of improvement is updated with the arrival of new sensory evidence, by incorporating a reward prediction error (RPE), which signals the mismatch between the expected (expected value) and perceived improvement. Consistent with this framework, neuroimaging studies of antidepressant placebo effects have demonstrated placebo-induced μ-opioid activation and increased blood-oxygen-level dependent (BOLD) responses in regions tracking expected values (e.g., ventromedial prefrontal cortex (vmPFC)) and RPEs (e.g., ventral striatum (VS)). In this study, we will demonstrate the causal contribution of reward learning signals (expected values and RPEs) to antidepressant placebo effects by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting the vmPFC and μ-opioid striatal RPE signal using pharmacological approaches. We hypothesized that antidepressant placebo expectancies are represented in the vmPFC (expected value) and updated by means of μ-opioid-modulated striatal learning signal. In a 3 × 3 factorial double-blind design, we will randomize 120 antidepressant-free individuals with depressive symptoms to one of three between-subject opioid conditions: the μ-opioid agonist buprenorphine, the μ-opioid antagonist naltrexone, or an inert pill. Within each arm, individuals will be assigned to receive three within-subject counterbalanced forms of TMS targeting the vmPFC-intermittent Theta Burst Stimulation (TBS) expected to potentiate the vmPFC, continuous TBS expected to de-potentiate the vmPFC, or sham TBS. These experimental manipulations will be used to modulate trial-by-trial reward learning signals and related brain activity during the Antidepressant Placebo functional MRI (fMRI) Task to address the following aims: (1) investigate the relationship between reward learning signals within the vmPFC-VS circuit and antidepressant placebo effects; (2) examine the causal contribution of vmPFC expected value computations to antidepressant placebo effects; and (3) investigate the causal contribution of μ-opioid-modulated striatal RPEs to antidepressant placebo effects. The proposed study will be the first to investigate the causal contribution of μ-opioid-modulated vmPFC-VS learning signals to antidepressant placebo responses, paving the way for developing novel treatments modulating learning processes and objective means of quantifying and potentially reducing placebo effects during drug development.
Trial registration: ClinicalTrials.gov Identifier: NCT04276259.
Keywords: antidepressant placebo effects; reinforcement learning; reward prediction error; theta burst stimulation; ventral striatum; ventromedial prefrontal cortex; μ-opioid system.
Figures




Similar articles
-
μ Opioid Antagonist Naltrexone Partially Abolishes the Antidepressant Placebo Effect and Reduces Orbitofrontal Cortex Encoding of Reinforcement.Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Oct;6(10):1002-1012. doi: 10.1016/j.bpsc.2021.02.009. Epub 2021 Mar 6. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021. PMID: 33684624 Free PMC article. Clinical Trial.
-
Neuroimaging Studies of Antidepressant Placebo Effects: Challenges and Opportunities.Front Psychiatry. 2019 Sep 24;10:669. doi: 10.3389/fpsyt.2019.00669. eCollection 2019. Front Psychiatry. 2019. PMID: 31616327 Free PMC article. Review.
-
Ventromedial Prefrontal Cortex Damage Is Associated with Decreased Ventral Striatum Volume and Response to Reward.J Neurosci. 2016 May 4;36(18):5047-54. doi: 10.1523/JNEUROSCI.4236-15.2016. J Neurosci. 2016. PMID: 27147657 Free PMC article.
-
Dynamic Feedback Between Antidepressant Placebo Expectancies and Mood.JAMA Psychiatry. 2023 Apr 1;80(4):389-398. doi: 10.1001/jamapsychiatry.2023.0010. JAMA Psychiatry. 2023. PMID: 36857039 Free PMC article. Clinical Trial.
-
Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity.Neuroimage Clin. 2015 Mar 24;8:1-31. doi: 10.1016/j.nicl.2015.03.016. eCollection 2015. Neuroimage Clin. 2015. PMID: 26110109 Free PMC article. Review.
Cited by
-
Using Drift Diffusion and RL Models to Disentangle Effects of Depression On Decision-Making vs. Learning in the Probabilistic Reward Task.Comput Psychiatr. 2024 May 3;8(1):46-69. doi: 10.5334/cpsy.108. eCollection 2024. Comput Psychiatr. 2024. PMID: 38774430 Free PMC article.
References
-
- Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002. April 10;287(14):1840–7. - PubMed
-
- Choi DW, Armitage R, Brady LS, Coetzee T, Fisher W, Hyman S, et al. Medicines for the mind: policy-based “pull” incentives for creating breakthrough CNS drugs. Neuron. 2014. November 5;84(3):554–63. - PubMed
-
- Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004. March;130(2):324–40. - PubMed
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials